SHIP cluster U-turns on Lucentis policy after price is slashed
A primary care trust cluster under the threat of legal action for recommending the use of an unlicensed drug has revoked the policy after the pharmaceutical company cut the price of the medicine.
You need to be a subscriber to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All HSJ news by sector, topic & region
- Breaking News announcements
- App for mobile and offline reading
- Comment and Daily Insights newsletters
- Regional roundup newsletters
- 10 expert briefings every fortnight (Premium only)
- Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)
Already a subscriber? Sign into your account here